The paradigm of surgical procedures is evolving, with clinical value underpinning sustained high growth in the global surgical robot market. Laparoscopic surgical robots account for nearly half of the market, representing the largest segment, yet they still possess significant long-term growth potential. International companies have established deep competitive moats through first-mover advantages, including physician usage habits, brand loyalty, comprehensive channel and after-sales service networks, and the feedback from vast amounts of surgical data for product iteration. They have also erected global patent protection barriers. Domestic surgical robot companies exhibit substantial long-term potential in both performance and valuation.

Surgical robots offer outstanding clinical value. Although robot-assisted surgeries initially incur higher costs compared to conventional procedures, they result in less trauma, fewer complications and repeat surgeries, shorter hospital stays, faster recovery times, better functional preservation, improved quality of life, and reduce the learning curve for surgeons, leading to significant long-term socio-economic benefits. Consequently, the application departments and types of procedures for surgical robots are gradually expanding, continuously enlarging the accessible market. According to Frost & Sullivan data, the global surgical robot market was valued at $21.2 billion in 2024 and is projected to reach $84.2 billion by 2033, reflecting a compound annual growth rate of 16.6% from 2024 to 2033.

In the first phase of the industry's development, international firms, led by the US market, dominated the sector, building excellent business models and strong moats. Key players like Intuitive Surgical and Stryker are primarily focused on the US, where penetration rates are relatively high. Leveraging the US market, these pioneers have established a stable "equipment + consumables/service" profit model through a flywheel effect: clinical value drives system installations, installations lead to more procedures, and procedures bind consumable usage. As this closed-loop ecosystem penetrates further into departmental procedure volumes, the advantages of surgical robot companies in the traditional surgical consumables market are becoming increasingly apparent.

In the next phase, non-US markets are becoming crucial growth drivers, and the rise of domestic players is expected to reshape the competitive landscape. Compared to the US market, non-US markets lag significantly in terms of installed base and procedure penetration rates. Growth rates for procedure volumes from companies like Intuitive Surgical indicate that non-US markets are now a major source of industry growth. European markets, with healthcare systems more focused on cost control, exhibit greater caution towards surgical robots compared to the US, with notable variations between regions. The Asia-Pacific and Latin American markets are poised for rapid growth. In China, increased supply from domestic surgical robot manufacturers, coupled with policy relaxation regarding procurement permits and the gradual establishment of a hospital fee structure for robotic surgeries, is expected to fuel a new wave of high growth.

Domestic companies are achieving rapid iteration and differentiated innovation, potentially matching the product capabilities of international leaders. Benefiting from China's engineering talent pool and local supply chain, they hold significant cost-performance advantages and are progressively building out marketing, training, and after-sales service systems. In the Chinese market, import substitution has already yielded significant results. By 2025, domestic companies such as MicroPort Robot and Jingfeng Medical are anticipated to begin scaling up volumes in overseas non-US markets. Leveraging their cost-performance and innovation advantages, domestic players are well-positioned to capture substantial market share in cost-sensitive overseas markets with low penetration rates.

Following the precedent set by Intuitive Surgical and Stryker, which have validated their business models and achieved high penetration primarily in the mature US market, domestic surgical robot companies possess considerable long-term potential for both financial performance and valuation. Companies suggested for attention include MicroPort Robot, Jingfeng Medical, Tinavi Medical Technologies, AK Medical, and Chunli Orthopedics. Risks include patent litigation, geopolitical tensions, currency fluctuations, and potential shortfalls in new product development, promotion, or market penetration rates.